Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Péter Kunovszki, Kata Judit Szántó, Judit Gimesi-Országh, Péter Takács, András Borsi, Anita Bálint, Klaudia Farkas, Ágnes Milassin, Péter L. Lakatos, Tamás Szamosi & Tamás Molnár. (2020) Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016. Expert Opinion on Biological Therapy 20:4, pages 443-449.
Read now
Read now
Steven J. Bots, Sabine Kuin, Cyriel Y. Ponsioen, Krisztina B. Gecse, Marjolijn Duijvestein, Geert R. D’Haens & Mark Löwenberg. (2019) Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. Scandinavian Journal of Gastroenterology 54:3, pages 281-288.
Read now
Read now
Articles from other publishers (40)
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollón, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik S Ding, Gabriele Dragoni, Federica Furfaro, Patrick F van Rheenen, Maria Chaparro, Javier P Gisbert, Edouard Louis & Konstantinos Papamichail. (2023) ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease. Journal of Crohn's and Colitis 17:7, pages 1031-1045.
Crossref
Crossref
Remi Mahmoud, Edo H.J. Savelkoul, Wout Mares, Rogier Goetgebuer, Ben J.M. Witteman, Daan B. de Koning, Sebastiaan A.C. van Tuyl, Itta Minderhoud, Maurice W.M. D. Lutgens, Dilek Akol-Simsek, Fiona D.M. van Schaik, Herma H. Fidder, Jeroen M. Jansen, Petra G.A. van Boeckel, Nofel Mahmmod, Carmen S. Horjus-Talabur Horje, Tessa E.H. Römkens, Jean-Frédéric Colombel, Frank Hoentjen, Bindia Jharap & Bas Oldenburg. (2023) Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 21:3, pages 750-760.e4.
Crossref
Crossref
Cong Dai, Yi-Nuo Wang, Wen-Ning Tian, Yu-Hong Huang & Min Jiang. (2023) Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Yiyoung Kwon, Eun Sil Kim, Yon Ho Choe & Mi Jin Kim. (2022) How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study. World Journal of Gastroenterology 28:28, pages 3666-3681.
Crossref
Crossref
Joseph Meredith, Paul Henderson, David C. Wilson & Richard K. Russell. (2021) Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence. Frontiers in Pediatrics 9.
Crossref
Crossref
Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im & Chang Hwan Choi. (2021) Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. Gut and Liver 15:5, pages 752-762.
Crossref
Crossref
Joseph Meredith, Paul Henderson, David C. Wilson, Johan Van Limbergen, Eytan Wine & Richard K. Russell. (2021) Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease—An International Survey of Practice. Journal of Pediatric Gastroenterology & Nutrition 73:1, pages 54-60.
Crossref
Crossref
Inessa Normatov, Daniela Fluxa, Jingzhou D Wang, Jacob E Ollech, George E Gulotta, Shivani Patel, Maria A Quintero, Bety De la Torre, Norma Solis, Oriana M Damas, Amar R Deshpande, David H Kerman, Maria T Abreu & David T Rubin. (2021) Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction. Crohn's & Colitis 360 3:3.
Crossref
Crossref
Remi Mahmoud, Chris van Lieshout, Geert W J Frederix, Bindia Jharap & Bas Oldenburg. (2021) Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. Journal of Crohn's and Colitis 15:5, pages 709-718.
Crossref
Crossref
Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon & Yun Mi Yu. (2021) Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease 12, pages 204062232110419.
Crossref
Crossref
Edouard Louis. (2020) Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. Frontiers in Medicine 6.
Crossref
Crossref
Chao Guo, Ka Wu, Xiaoliu Liang, Yujia Liang & Rong Li. (2019) Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. Pharmacological Research 148, pages 104455.
Crossref
Crossref
María Chaparro, María G. Donday, Manuel Barreiro-de Acosta, Eugeni Domènech, María Esteve, Valle García-Sánchez, Pilar Nos, Julián Panés, Concepción Martínez, Javier P. Gisbert, F. Abad, M. Aguas Peris, E. Agüero Tejado, C. Alba, M. Albert, H. Alemán, A. Algaba, I. Alonso Abreu, M.P. Amador, M. Amat, T. Angueira, C. Arajol, L. Arias-González, A. Arrondo Velasco, M. Baldán, B. Bardán García, A. Bargalló García, M. Barreiro de Acosta, J. Barrio Andrés, G. Bastida Paz, I. Bastón Rey, L. Batista, M. Bellver Martínez, B. Beltrán Niclós, J.M. Benítez, Y. Ber Nieto, F. Bermejo, D. Bernardo, I. Blázquez Gómez, A. Bouhmidi Assakali, D. Busquets Casals, J.L. Cabriada Nuño, X. Calvet Calvo, M.V. Calvo Hernández, M. Calvo, B. Camps, A.Y. Carbajo, G. Cardona Peitx, T. Caro-Patón, M. Carrillo Palau, S. Carrión Bolorino, M.J. Casanova, J.A. Casellas Valdé, A. Castaño García, B. Castro Senosiain, D. Ceballos, E. Cerrillo, S. Chacón Martínez, F. Consuelo Cañete Pizarro, M.L. de Castro Parga, M. de Miguel, R. de Francisco García, M.D. de la Cruz Ramírez, J. del Hoyo Francisco, P. Delgado Guillena, T. Desongles Corrales, A. Echarri Piudo, E. Espino Paisan, M. Espona Quer, A. Fernández Pordomingo, J.L. Fernández Forcelledo, S. Fernández-Tomé, R. Ferreiro Iglesias, I. Ferrer Bradley, A. Ferrer, A. Figueroa, M. Gallach Montero, P. García Iglesias, C. García García-Lezcún, L. García Ramírez, M.J. García García, O. García-Bosh, A. Garre, T. Giménez Poderós, L. Gómez Irwin, B. Gómez Pastrana, E. Gómez Delgado, Y. González Lama, Á. Gracia García, B. Gracia García, J. Guardiola, I. Guerra, E. Guerra, V. Guillot, S. Gustmancher Saiz, A. Gutiérrez Casbas, V. Hernández Ramírez, M.M. Hernando Verdugo, B. Hernández Muniesa, R. Hernanz Chaves, J.M. Herrera Justiniano, J Hinojosa del Val, S Ibáñez Feijoo, M Iborra Colomino, E Iglesias Flores, E. Izquierdo García, M J Sampedro González, A J. Lucendo, N Jiménez García, E. Leo Carnerero, I. Loizaga Díaz, A López de Torre Querejazu, P López Sánchez, J Luis Parras, M Maia Boscá, M Mañosa, S Marín Pedrosa, A Marín, Á Marinero, I Marín-Jiménez, L Márquez Mosquera, JL Márquez Galán, E Martín Arranz, MD Martín Arranz, J Martínez Cadilla, JM Martínez Sesmero, B Martínez Sánchez, V Matallana, MI Mateos Hernández, AG McNicholl, R Mejuto Fernández, L Melcarne, L Menchén, J Méndez-Castrillón Rodríguez, O Merino Ochoa, M Mínguez, G Molas Ferrer, M Montoro Huguet, A Montserrat Torres, F Mora, I Moraleja Yudego, VJ Morales Alvarado, L Morales Martínez, A Morell, C Motos García, F Muñoz Alonso, MC Muñoz Villafranca, JE Muñoz, A Mur, Ó Nantes, P Navarro, M Navarro- Llavat, P Nos Mateu, A Núñez Alonso, A Núñez Ortiz, D Olivares, V Ollero Pena, J Orobitg, L Ortega, J Ortiz de Zárate, H Pallarés Manrique, A Paradela Carreiro, L Peral Ballester, S Pereira Bueno, I Pérez Martínez, JR Pineda Mariño, C Piñero Pérez, A Planas Giner, MR Plaza Santos, Á Ponferrada Díaz, J Poza Cardón, V Prieto Vicente, L Puchades, L Ramos López, S Redondo, S Riestra Menéndez, M Rivero Tirado, I Rodríguez Lago, C Rodríguez Gutiérrez, E Rodríguez, S Romero Izquierdo, S Rubio Iturria, MB Ruiz Antorán, A Ruiz, LF Salazar, A Sánchez Ulayar, E Sánchez Gómez, C Sánchez, C Sangrador, K Serra, K Spicakova, C Suárez Ferrer, A Talavera Fabuel, C Taxonera, M Tordera, E Torrella Cortés, J Tosca, C Trigo Salado, F Uriarte Estefanía, M Van Domselaar, JM Vázquez Morón, P Ventura López, M Vera, M Vicuña Arregui, A Villoria Ferrer, T Virgós Aller & D Yáñez Feria. (2019) Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. Therapeutic Advances in Gastroenterology 12, pages 175628481987420.
Crossref
Crossref
Edouard Louis. (2018) Stopping Biologics in IBD—What Is the Evidence?. Inflammatory Bowel Diseases 24:4, pages 725-731.
Crossref
Crossref
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska & Edouard Louis. (2018) European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:1, pages 17-31.
Crossref
Crossref
Hang Hock Shim & Cynthia H. Seow. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
141
162
.
Masanao Nasuno, Maki Miyakawa, Hiroki Tanaka & Satoshi Motoya. (2017) Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study. Digestion 95:1, pages 67-71.
Crossref
Crossref
M J Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, M Rojas-Feria, A Jauregui-Amezaga, S García-López, J M Huguet, F Arguelles-Arias, M Aicart, I Marín-Jiménez, M Gómez-García, F Muñoz, M Esteve, L Bujanda, X Cortés, J Tosca, J R Pineda, M Mañosa, J Llaó, J Guardiola, I Pérez-Martínez, C Muñoz, Y González-Lama, J Hinojosa, J M Vázquez, M P Martinez-Montiel, G E Rodríguez, R Pajares, M F García-Sepulcre, A Hernández-Martínez, J L Pérez-Calle, B Beltrán, D Busquets, L Ramos, F Bermejo, J Barrio, M Barreiro-de Acosta, O Roncedo, X Calvet, D Hervías, F Gomollón, M Domínguez-Antonaya, G Alcaín, B Sicilia, C Dueñas, A Gutiérrez, R Lorente-Poyatos, M Domínguez, S Khorrami, C Taxonera, A Rodríguez-Pérez, A Ponferrada, M Van Domselaar, M L Arias-Rivera, O Merino, E Castro, J M Marrero, M Martín-Arranz, B Botella, L Fernández-Salazar, D Monfort, V Opio, A García-Herola, M Menacho, Ramírez-de P la Piscina, D Ceballos, P Almela, M Navarro-Llavat, V Robles-Alonso, A B Vega-López, I Moraleja, M T Novella, C Castaño-Milla, A Sánchez-Torres, J M Benítez, C Rodríguez, L Castro, E Garrido, E Domènech, E García-Planella & J P Gisbert. (2017) Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology 112:1, pages 120-131.
Crossref
Crossref
Petra Baji, László Gulácsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin Brodszky, Fanni Rencz & Péter L. Lakatos. (2016) Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues 10, pages 85-90.
Crossref
Crossref
M. Anthony Sofia & David T. Rubin. (2016) Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therapeutic Advances in Gastroenterology 9:4, pages 548-559.
Crossref
Crossref
María Chaparro & Javier P. Gisbert. (2016) Nuevas moléculas en el tratamiento de la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 39:6, pages 411-423.
Crossref
Crossref
María Chaparro & Javier P. Gisbert. (2016) New molecules in the treatment of inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 39:6, pages 411-423.
Crossref
Crossref
Javier P Gisbert, Alicia C Marín & María Chaparro. (2016) The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 111:5, pages 632-647.
Crossref
Crossref
Joana Torres, Marília Cravo & Jean-Frédéric Colombel. (2016) Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Portuguese Journal of Gastroenterology 23:3, pages 153-161.
Crossref
Crossref
N. A. Kennedy, B. Warner, E. L. Johnston, L. Flanders, P. Hendy, N. S. Ding, R. Harris, A. S. Fadra, C. Basquill, C. A. Lamb, F. L. Cameron, C. D. Murray, M. Parkes, I. Gooding, T. Ahmad, D. R. Gaya, S. Mann, J. O. Lindsay, J. Gordon, J. Satsangi, A. Hart, S. McCartney, P. Irving & C. W. Lees. (2016) Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Alimentary Pharmacology & Therapeutics 43:8, pages 910-923.
Crossref
Crossref
LILI XU, LILI MA, JINGJING LIAN, JIAYIN YANG & SHIYAO CHEN. (2016) Gene expression alterations in inflamed and unaffected colon mucosa from patients with mild inflammatory bowel disease. Molecular Medicine Reports 13:3, pages 2729-2735.
Crossref
Crossref
Javier P. Gisbert, Manuel Barreiro-de Acosta, María Esteve, Valle García-Sánchez, Fernando Gomollón, Jordi Guardiola, Joaquin Hinojosa, Maria-Dolores Martín Arranz, Miguel Minguez, Carlos Taxonera & Isabel Vera. (2016) Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis. Inflammatory Bowel Diseases 22:3, pages 583-598.
Crossref
Crossref
Marcello Cintolo. (2016) Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World Journal of Gastrointestinal Pathophysiology 7:1, pages 1.
Crossref
Crossref
O. V. Knyazev, A. I. Parfenov, A. G. Konoplyannikov & O. N. Boldyreva. (2016) Use of mesenchymal stem cells in the combination therapy of ulcerative colitis. Terapevticheskii arkhiv 88:2, pages 44.
Crossref
Crossref
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel & Jack Satsangi. (2015) Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 149:7, pages 1716-1730.
Crossref
Crossref
Ellen H. Bailey & Sean C. Glasgow. (2015) Challenges in the Medical and Surgical Management of Chronic Inflammatory Bowel Disease. Surgical Clinics of North America 95:6, pages 1233-1244.
Crossref
Crossref
Sarah O’Donnell, Joanne M. Stempak, A. Hillary Steinhart & Mark S. Silverberg. (2015) Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn’s disease. Journal of Crohn's and Colitis 9:10, pages 830-836.
Crossref
Crossref
Eun Hye Kim, Duk Hwan Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim & Jae Hee Cheon. (2015) Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut and Liver 9:5.
Crossref
Crossref
J. P. Gisbert, A. C. Marín & M. Chaparro. (2015)
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐
TNF
therapy
. Alimentary Pharmacology & Therapeutics 42:4, pages 391-405.
Crossref
Crossref
Konstantinos Papamichael, Niels Vande Casteele, Ann Gils, Sophie Tops, Scott Hauenstein, Sharat Singh, Fred Princen, Gert Van Assche, Paul Rutgeerts, Severine Vermeire & Marc Ferrante. (2015) Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. Clinical Gastroenterology and Hepatology 13:6, pages 1103-1110.
Crossref
Crossref
Aurelien Amiot & Laurent Peyrin-Biroulet. (2014) Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic Advances in Gastroenterology 8:2, pages 66-82.
Crossref
Crossref
Konstantinos Papamichael. (2015) Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World Journal of Gastroenterology 21:16, pages 4773.
Crossref
Crossref
Anita Annaházi & Tamás Molnár. (2015) Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015, pages 1-18.
Crossref
Crossref
Dario Sorrentino, Peter Nash, Monica Viladomiu, Raquel Hontecillas & Josep Bassaganya-Riera. (2014) Stopping Anti-TNF Agents in Patients with Crohnʼs Disease in Remission. Inflammatory Bowel Diseases 20:4, pages 757-766.
Crossref
Crossref
Klaudia Farkas & Tamás Molnár. (2014) Biological Therapy in IBD—Is There Any Optimal End Point?. Health 06:11, pages 1296-1299.
Crossref
Crossref